The FDA's complete response letter highlights insufficient efficacy evidence for bevacizumab-vikj in treating wet AMD, despite previous safety confirmations. NORSE EIGHT study failed its primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results